
It is a research breakthrough that has been touted as the biggest development in Alzheimer’s disease research for a quarter …

New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by …

The old adage that everyone is unique holds a lot of water when it comes to cancer treatment. Research has …

Merck KGaA announced that is has created the Merck Foundation and has appointed Rasha Kelej as its CEO. The role …

The EMA and the FDA have announced that they have developed a joint proposal to promote more efficient means of …

NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …

DeepMind’s deal with the NHS to develop an app that is able to detect possible kidney damage involved 1.6 million …

A research team at the Babraham Institute in Cambridge, UK has revealed a new method to detect and monitor large-scale …

When they first came along, webinars were the equivalent of an outside broadcast unit, lots of hardware, dedicated studios and …

The growing issue of antibiotic resistance is finding itself increasingly central in pharma’s priorities, though many still argue that the …

Stada, the German generic drugs manufacturer, saw its two most senior executives leave the company for ‘personal reasons’. Matthias Wiedenfels, …

India’s biggest pharma firm has signed a $55 million long-term manufacturing deal with Korea’s Samsung BioLogics for Tildrakizumab, an investigational …

Johnson & Johnson will face a lawsuit after 700 Australian women launched a class action suit over the failures of …

England’s top Chief Medical Officer has called for routine DNA testing to become standard on the NHS in a bid …

Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will …

AstraZeneca is expected to generate almost $600 million from just two drug sales: Zoming, a migraine therapy, and Seloken, a …

The development of innovative treatments for neurological disorders such as dementia has stagnated over the past decade despite being an …

Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success …

With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up …

Pfizer has revealed that its drug Besponsa (inotuzumab ozogamicin) has received approval from the European Commission as a monotherapy for …